The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Interleukin‐8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models
Open accessAbstract
Interleukin‐8 (IL‐8), a chemokine with a defining CXC amino acid motif, is known to possess tumorigenic and proangiogenic properties. Overexpression of IL‐8 has been detected in many human tumors, including colorectal cancer (CRC), and is associated with poor prognosis. The goal of our study was to determine the role of IL‐8 overexpression in CRC cells in vitro and in vivo. We stably transfected the IL‐8 cDNA into two human colon cancer cell lines, HCT116 and Caco2, and selected IL‐8‐secreting transfectants. Real‐time RT‐PCR confirmed that IL‐8 mRNA was overexpressed in IL‐8 transfectants with 45‐ to 85‐fold higher than parental cells. The IL‐8‐transfected clones secreted 19‐ to 28‐fold more IL‐8 protein than control and parental cells as detected by ELISA. The IL‐8 transfectants demonstrated increased cellular proliferation, cell migration and invasion based on functional assays. Growth inhibition studies showed that IL‐8 overexpression lead to a significant resistance to oxaliplatin (p< 0.0001). Inhibition of IL‐8 overexpression with small interfering RNA reversed the observed increases in tumorigenic functions and oxaliplatin resistance, suggesting that IL‐8 not only provides a proliferative advantage but also promotes the metastatic potential of colon cancer cells. Using a tumor xenograft model, IL‐8‐expressing cells formed significantly larger tumors than the control cells with increased microvessel density. Together, these findings indicate that overexpression of IL‐8 promotes tumor growth, metastasis, chemoresistance and angiogenesis, implying IL‐8 to be an important therapeutic target in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Rollins, B. J. (1997) · Blood · doi:10.1182/blood.v90.3.909 · Cited by 1,984
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536
Essential involvement of interleukin-8 (IL-8) in acute inflammation
Harada, A., Sekido, N., Akahoshi, T., Wada, T., Mukaida, N., & Matsushima, K. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.56.5.559 · Cited by 1,041
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
Sparmann, A., & Bar-Sagi, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.028 · Cited by 851
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
Brat, D. J., Bellail, A. C., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001061 · Cited by 760
Interleukin-8 and human cancer biology
Xie, K. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00016-8 · Cited by 689
Rollins, B. J. (1997) · PubMed · Cited by 603
Role of chemokines in tumor growth
Raman, D., Baugher, P. J., Thu, Y. M., & Richmond, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.05.013 · Cited by 578
Heidemann, J., Ogawa, H., Dwinell, M. B., Rafiee, P., Maaser, C., Gockel, H. R., Otterson, M. F., Ota, D. M., Lügering, N., Domschke, W., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208231200 · Cited by 476
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor.
Schadendorf, D., Möller, A., Algermissen, B., Worm, M., Sticherling, M., & Czarnetzki, B. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2667 · Cited by 412
Cancer CXC chemokine networks and tumour angiogenesis
Strieter, R. M., Burdick, M. D., Mestas, J., Gomperts, B., Keane, M. P., & Belperio, J. A. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.006 · Cited by 410
Ugurel, S., Rappl, G., Tilgen, W., & Reinhold, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.577 · Cited by 399
Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.-D., Gudas, J. M., & Bar-Eli, M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64164-8 · Cited by 361
Benoy, I. H., Salgado, R., Van Dam, P., Geboers, K., Van Marck, E., Scharpé, S., Vermeulen, P. B., & Dirix, L. Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0812 · Cited by 356
Interleukin-8 Is a Molecular Determinant of Androgen Independence and Progression in Prostate Cancer
Araki, S., Omori, Y., Lyn, D., Singh, R. K., Meinbach, D. M., Sandman, Y., Lokeshwar, V. B., & Lokeshwar, B. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1162 · Cited by 275
Merritt, W. M., Lin, Y. G., Spannuth, W. A., Fletcher, M. S., Kamat, A. A., Han, L. Y., Landen, C. N., Jennings, N., De Geest, K., Langley, R. R., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn024 · Cited by 257
Ueda, T., Shimada, E., & Urakawa, T. (1994) · Journal of Gastroenterology · doi:10.1007/bf02361238 · Cited by 214
Li, A., Varney, M. L., & Singh, R. K. (2001) · PubMed · Cited by 214
Schultheis, A. M., Lurje, G., Rhodes, K. E., Zhang, W., Yang, D., Garcia, A. A., Morgan, R., Gandara, D., Scudder, S., Oza, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0351 · Cited by 182
Self-citationCowden Dahl, K. D., Symowicz, J., Ning, Y., Gutierrez, E., Fishman, D. A., Adley, B. P., Stack, M. S., & Hudson, L. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5046 · Cited by 182
Self-citationYUAN, A., YANG, P.-C., YU, C.-J., CHEN, W.-J., LIN, F.-Y., KUO, S.-H., & LUH, K.-T. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.5.2002108 · Cited by 173
Green, A. R., Green, V. L., White, M. C., & Speirs, V. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970917)72:6<937::aid-ijc3>3.0.co;2-q · Cited by 137
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer
Lurje, G., Zhang, W., Schultheis, A. M., Yang, D., Groshen, S. G., Hendifar, A. E., Husain, H., Gordon, M. A., Nagashima, F., Chang, H.-M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn368 · Cited by 135
Self-citationKido, S., Kitadai, Y., Hattori, N., Haruma, K., Kido, T., Ohta, M., Tanaka, S., Yoshihara, M., Sumii, K., Ohmoto, Y., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00147-2 · Cited by 132
Wilson, C., Purcell, C., Seaton, A., Oladipo, O., Maxwell, P. J., O’Sullivan, J. M., Wilson, R. H., Johnston, P. G., & Waugh, D. J. J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143826 · Cited by 127
Hoffmann, E., Thiefes, A., Kettner-Buhrow, D., Dittrich‐Breiholz, O., Schneider, H., Resch, K., & Kracht, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407071200 · Cited by 108
Interleukin 8: An Autocrine Growth Factor for Human Ovarian Cancer
Xu, L., & Fidler, I. J. (2001) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504001108747567 · Cited by 107
Kaminska, J. A., Nowacki, M. P., Kowalska, M. M., Rysińska, A., Chwaliński, M., Fuksiewicz, M., Michalski, W., & Chechlińska, M. (2005) · Tumor Biology · doi:10.1159/000086951 · Cited by 107
Wilson, C., Wilson, T. R., Johnston, P. G., Longley, D. B., & Waugh, D. J. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0148 · Cited by 100
Larco, J. E. D., Wuertz, B. R. K., Manivel, J. C., & Furcht, L. T. (2001) · PubMed · Cited by 75
Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report
Yokoe, T., lino, Y., & Morishita, Y. (2000) · Breast Cancer · doi:10.1007/bf02967458 · Cited by 66
Rakitina, T. V., Vasilevskaya, I. A., & O'Dwyer, P. J. (2003) · PubMed · Cited by 60
Dobreva, I., Waeber, G., James, R. W., & Widmann, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508857200 · Cited by 50
Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis
Lane, H. C. (2006) · International Immunology · doi:10.1093/intimm/dxl064 · Cited by 37
Cited by
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Ha, H., Debnath, B., & Neamati, N. (2017) · Theranostics · doi:10.7150/thno.15625 · Cited by 789
The CXCL8-CXCR1/2 pathways in cancer
Liu, Q., Li, A., Tian, Y., Wu, J. D., Liu, Y., Li, T., Chen, Y., Han, X., & Wu, K. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.08.002 · Cited by 662
Bettini, S., Boutet-Robinet, E., Cartier, C., Coméra, C., Gaultier, E., Dupuy, J., Naud, N., Taché, S., Grysan, P., Reguer, S., et al. (2017) · Scientific Reports · doi:10.1038/srep40373 · Cited by 442
Metadata
- Authors
- Ning, Y., Manegold, P. C., Hong, Y. K., Zhang, W., Pohl, A., Lurje, G., Winder, T., Yang, D., LaBonte, M. J., Wilson, P. M., Ladner, R. D., & Lenz, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-03-08
- Volume
- 128
- Issue
- 9
- Pages
- 2038-2049
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1973033965
- Cited by
- 406
- References
- 40
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.